Prevalence of Occult Hepatitis B Virus Infection in Blood Donors with Negative ID-NAT in Switzerland

Overview

Journal Transfus Med Hemother

Specialty Hematology

Date 2023 Jan 19

PMID 36654973

Authors

Andrea Zbinden

Judith Ries

Patrick M Redli

Cyril Shah

Andreas Glauser

David Goslings

Daniela Huzly

Jurg Boni

Jochen Gottschalk

Beat M Frey

Affiliations

Soon will be listed here.

Abstract

Introduction: Screening of hepatitis B surface antigen (HBsAg) and individual-donation nucleic acid amplification testing (ID-NAT) of blood donors have become standard to detect hepatitis B virus (HBV) infection. However, there is still a residual risk of HBV transmission by blood components of donors suffering from occult HBV infection (OBI). Therefore, many countries implemented universal testing of anti-HBV core antigen (anti-HBc) antibodies in order to increase blood safety. In Switzerland, anti-HBc testing is not part of the routine blood donor-screening repertoire. Therefore, we sought to assess prevalence of donors with OBI in a Swiss blood donor collective.

Methods: Blood donations were prospectively investigated for the presence of anti-HBc antibodies during two time periods (I: all donors, March 2017; II: first-time donors only, April 2017 until February 2018). Anti-HBc-positive findings were confirmed by an anti-HBc neutralization test. Discarded plasma samples of anti-HBc-confirmed positive donors were ultracentrifuged and subsequently retested by regular HBV-ID-NAT to search for traces of HBV.

Results: During time period I, 78 (1.6%) individuals out of 4,923 donors were confirmed anti-HBc-positive. Sixty-nine (88%) anti-HBc-positive samples were available and processed by ultracentrifugation followed by repeat HBV-ID-NAT. Four samples (5.8%) were found positive for HBV DNA. Sixty-five (94.2%) samples remained HBV NAT-negative upon ultracentrifugation. During time period II, 56 (0.9%) donor samples out of 6,509 exhibited anti-HBc-confirmed positive. Fifty-five (98%) samples could be reassessed by HBV-ID-NAT upon ultracentrifugation. Three (5.5%) samples contained HBV DNA and 52 (94.5%) samples remained HBV NAT-negative.

Conclusion: Overall, we detected 7 viremic OBI carriers among 11,432 blood donors, which tested negative for HBV by standard HBV-ID-NAT and HBsAg screening. In contrast, OBI carriers showed positive anti-HBc findings which could be confirmed in 83.8% of the cases. Thus, OBI might be missed by the current HBV screening process of Swiss blood donors. We suggest to review current HBV screening algorithm. Extended donor screening by anti-HBc testing may unmask OBI carriers and contribute to blood safety for the recipient of blood products.

Citing Articles

Analysis of hepatitis B Virus Test results among blood donors in Chongqing, China.

Wei L, Chen M, Wang F, Li M, Liu D, Xie C BMC Infect Dis. 2024; 24(1):857.

PMID: 39179973 PMC: 11342658. DOI: 10.1186/s12879-024-09753-8.

Efficacy of combined HBsAg, anti-HBc and anti-HBs screening in minimizing transfusion transmission risk of hepatitis B infection in low resource setting.

Athalye S, Patil A, Khargekar N, Shinde S, Chavan S, Dixit A Heliyon. 2024; 10(3):e25805.

PMID: 38356514 PMC: 10865305. DOI: 10.1016/j.heliyon.2024.e25805.

Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing, China.

Zhou Y, Yu J, Zhou L, Xu B, Dai Y, Wang H Hum Vaccin Immunother. 2023; 19(1):2206774.

PMID: 37103976 PMC: 10142315. DOI: 10.1080/21645515.2023.2206774.

Advancing blood transfusion safety using molecular detection in the country of Georgia.

Alkhazashvili M, Bloch E, Shadaker S, Kuchuloria T, Getia V, Turdziladze A Transfus Clin Biol. 2023; 30(3):307-313.

PMID: 36907246 PMC: 10958484. DOI: 10.1016/j.tracli.2023.03.002.

References

Kiely P, Margaritis A, Seed C, Yang H . Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection. Transfusion. 2014; 54(8):2084-91. DOI: 10.1111/trf.12556. View

Huzly D, Nassal M, Vorreiter J, Falcone V, Neumann-Haefelin D, Gerlich W . Simple confirmatory assay for anti-HBc reactivity. J Clin Virol. 2011; 51(4):283-4. DOI: 10.1016/j.jcv.2011.05.009. View

Niederhauser C, Weingand T, Candotti D, Maier A, Tinguely C, Wuillemin W . Fatal outcome of a hepatitis B virus transfusion-transmitted infection. Vox Sang. 2010; 98(4):504-7. DOI: 10.1111/j.1423-0410.2009.01304.x. View

Candotti D, Boizeau L, Laperche S . Occult hepatitis B infection and transfusion-transmission risk. Transfus Clin Biol. 2017; 24(3):189-195. DOI: 10.1016/j.tracli.2017.06.014. View

Leung V, Lee C, Chau T, Cheung W, Lo F, Lai K . A probable case of transfusion-transmitted hepatitis B virus infection in an immunosuppressed recipient caused by an occult HBV-infected donor with negative ID-NAT. Transfus Med. 2010; 20(4):276-7. DOI: 10.1111/j.1365-3148.2010.00997.x. View

Candotti D, Assennato S, Laperche S, Allain J, Levicnik-Stezinar S . Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2018; 68(2):313-321. DOI: 10.1136/gutjnl-2018-316490. View

Fiedler S, Oberle D, Chudy M, Scheiblauer H, Henseler O, Halbauer J . Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015). Vox Sang. 2019; 114(5):443-450. PMC: 6849742. DOI: 10.1111/vox.12770. View

Caviglia G, Olivero A, Ciancio A, Tandoi F, Troshina G, Rosso C . Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagn Microbiol Infect Dis. 2020; 96(4):114985. DOI: 10.1016/j.diagmicrobio.2020.114985. View

OBrien S, Fearon M, Yi Q, Fan W, Scalia V, Muntz I . Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion. 2007; 47(10):1809-15. DOI: 10.1111/j.1537-2995.2007.01396.x. View

10.

van de Laar T, der Kreek T, Molenaar-de Backer M, Hogema B, Zaaijer H . The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country. Transfusion. 2014; 55(6):1206-13. DOI: 10.1111/trf.12962. View

11.

Styles C, Cheng A, Hoad V, Kiely P, Watson M, Seed C . Excluding Occult Hepatitis B Infection before Assigning False-Positive Status to Non-Repeatable NAT Reactivity: Concerning Stolz et al. "Safe-Testing Algorithm for Individual-Donation Nucleic Acid Testing: 10 Years of Experience in a Low-Prevalence.... Transfus Med Hemother. 2020; 47(3):272-274. PMC: 7315221. DOI: 10.1159/000502552. View

12.

Weusten J, van Drimmelen H, Vermeulen M, Lelie N . A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios. Transfusion. 2017; 57(3pt2):841-849. DOI: 10.1111/trf.14050. View

13.

Richard J, Schaetti C, Basler S, Masserey Spicher V . Reduction of acute hepatitis B through vaccina-tion of adolescents with no decrease in chronic hepatitis B due to immigration in a low ende-micity country. Swiss Med Wkly. 2017; 147:w14409. DOI: 10.4414/smw.2017.14409. View

14.

Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H . Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion. 2007; 47(7):1197-205. DOI: 10.1111/j.1537-2995.2007.01276.x. View

15.

van de Laar T, Hogema B, Molenaar-de Backer M, der Kreek T, Zaaijer H . Blood donor screening in the Netherlands: Universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing. Transfusion. 2021; 61(7):2116-2124. DOI: 10.1111/trf.16420. View

16.

Miletic M, Bingulac-Popovic J, Stojic Vidovic M, Hecimovic A, Berendika M, Babic I . Anti-HBc prevalence among Croatian blood donors in a 14-year period (2004-2017): Assessment of trends, risks and need for implementing routine testing. Transfus Clin Biol. 2019; 26(4):257-262. DOI: 10.1016/j.tracli.2019.05.001. View

17.

Harvala H, Reynolds C, Gibney Z, Derrick J, Ijaz S, Davison K . Hepatitis B infections among blood donors in England between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety?. Transfusion. 2021; 61(8):2402-2413. DOI: 10.1111/trf.16543. View

18.

Lieshout-Krikke R, van Kraaij M, Danovic F, Zaaijer H . Rare transmission of hepatitis B virus by Dutch donors with occult infection. Transfusion. 2015; 56(3):691-8. DOI: 10.1111/trf.13401. View

19.

Seed C, Maloney R, Kiely P, Bell B, Keller A, Pink J . Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme. Vox Sang. 2014; 108(2):113-22. DOI: 10.1111/vox.12198. View

20.

Irsch J, Lin L . Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™. Transfus Med Hemother. 2011; 38(1):19-31. PMC: 3132977. DOI: 10.1159/000323937. View